Reports Q3 revenue $114.57M vs. $0 last year. As of September 30, 2025, Lipocine (LPCN) had $15.1M of unrestricted cash, cash equivalents and marketable investment securities compared to $21.6M at December 31, 2024.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LPCN: